Scholarlink

<p>CLN1 disease, one of the most severe forms of neuronal ceroid lipofuscinosis (NCLs or Batten disease), is a rapidly progressing pediatric neurodegenerative disorder caused by mutations in the <i>PPT1</i> gene. The disease is characterized by lysosomal storage accumulation, an early onset neuroimmune response, motor impairment, and premature death. N-acetyl-L-leucine (NALL), an orally bioavailable modified amino acid, has demonstrated clinical efficacy in Niemann–Pick type C and other lysosomal storage disorders. Here, we assessed the efficacy of chronic NALL treatment in the <i>Ppt1</i><sup><i>−/−</i></sup> mouse model of CLN1 disease. Mice received NALL (0.1&#xa0;g/kg/day) in chow either from weaning (1 month, presymptomatic) or from 4 months (symptomatic) until 7 months (normal disease endstage), with additional survival cohorts. NALL treatment did not extend survival in <i>Ppt1</i><sup><i>−/−</i></sup> mice and produced no significant improvement in gait coordination or rotarod performance, with only minimal improvements in select gait variability parameters in presymptomatically treated mice. Histological analyses revealed no reduction in microglial or astrocyte activation, nor in storage material accumulation, key CLN1 disease-associated phenotypes. These findings indicate that NALL monotherapy has limited therapeutic efficacy in CLN1 disease mice and suggest that its mechanisms of action may not address the underlying pathophysiology of this disorder.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Limited therapeutic efficacy of N-acetyl-L-leucine in a mouse model of CLN1 disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Ewa A. Ziółkowska,
  • Nicole A. Pagán Torres,
  • Hsintsung Chen,
  • Letitia L. Williams,
  • Elizabeth M. Eultgen,
  • Agnieszka Nowacka,
  • Joshua T. Dearborn,
  • Hemanth R. Nelvagal,
  • Ineka T. Whiteman,
  • Frances M. Platt,
  • Jonathan D. Cooper

摘要

CLN1 disease, one of the most severe forms of neuronal ceroid lipofuscinosis (NCLs or Batten disease), is a rapidly progressing pediatric neurodegenerative disorder caused by mutations in the PPT1 gene. The disease is characterized by lysosomal storage accumulation, an early onset neuroimmune response, motor impairment, and premature death. N-acetyl-L-leucine (NALL), an orally bioavailable modified amino acid, has demonstrated clinical efficacy in Niemann–Pick type C and other lysosomal storage disorders. Here, we assessed the efficacy of chronic NALL treatment in the Ppt1−/− mouse model of CLN1 disease. Mice received NALL (0.1 g/kg/day) in chow either from weaning (1 month, presymptomatic) or from 4 months (symptomatic) until 7 months (normal disease endstage), with additional survival cohorts. NALL treatment did not extend survival in Ppt1−/− mice and produced no significant improvement in gait coordination or rotarod performance, with only minimal improvements in select gait variability parameters in presymptomatically treated mice. Histological analyses revealed no reduction in microglial or astrocyte activation, nor in storage material accumulation, key CLN1 disease-associated phenotypes. These findings indicate that NALL monotherapy has limited therapeutic efficacy in CLN1 disease mice and suggest that its mechanisms of action may not address the underlying pathophysiology of this disorder.